Literature DB >> 19168248

Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?

Andrij Abramyuk1, Sergey Tokalov, Klaus Zöphel, Arne Koch, Kornelia Szluha Lazanyi, Charles Gillham, Thomas Herrmann, Nasreddin Abolmaali.   

Abstract

BACKGROUND AND
PURPOSE: Local failure is a significant issue following radiotherapy (RT) for patients with non-small cell lung cancer (NSCLC). The aim of this study was to find out whether FDG-PET/CT is capable to predict tumor relapse location in patients with NSCLC, in particular to determine high risk tumors' subvolumes responsible for local failure.
MATERIAL AND METHODS: Ten patients with locoregional relapse of NSCLC underwent FDG-PET/CT before, during, and in the 4-12 months following curative chemoradiotherapy (ChRT, 66 Gy) using a combined PET/CT scanner. Morphologic and metabolic tumor volumetry and an evaluation of FDG-uptake dynamics were performed.
RESULTS: CT showed partial reduction of tumor volume after RT in all patients. PET-revealed partial in eight patients and complete metabolic response in two patients during RT. Six to nine months after RT, local failure was diagnosed in all patients with both methods. Tumor recurrences were localized mostly in the most active ones of pre-therapeutically metabolic regions of the primary tumor.
CONCLUSIONS: Local failure in NSCLC appears most common at the primary site and within the irradiated target volume with the highest FDG uptake. This observation may be useful for further optimization of radiotherapy of NSCLC, for example, by the application of additional radiation dose to subvolumes of primary tumors with higher FDG uptake.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168248     DOI: 10.1016/j.radonc.2009.01.003

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  25 in total

Review 1.  Individualization of cancer treatment from radiotherapy perspective.

Authors:  Ala Yaromina; Mechthild Krause; Michael Baumann
Journal:  Mol Oncol       Date:  2012-02-09       Impact factor: 6.603

2.  In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.

Authors:  Catharina M L Zegers; Wouter van Elmpt; Bart Reymen; Aniek J G Even; Esther G C Troost; Michel C Ollers; Frank J P Hoebers; Ruud M A Houben; Jonas Eriksson; Albert D Windhorst; Felix M Mottaghy; Dirk De Ruysscher; Philippe Lambin
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.

Authors:  M Dosani; R Yang; M McLay; D Wilson; M Liu; C J Yong-Hing; J Hamm; C R Lund; R Olson; D Schellenberg
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

4.  Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer.

Authors:  Wouter van Elmpt; Michel Ollers; Anne-Marie C Dingemans; Philippe Lambin; Dirk De Ruysscher
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

Review 5.  [PET/CT for diagnostics and therapy stratification of lung cancer].

Authors:  C Kratochwil; U Haberkorn; F L Giesel
Journal:  Radiologe       Date:  2010-08       Impact factor: 0.635

6.  A Bayesian network approach for modeling local failure in lung cancer.

Authors:  Jung Hun Oh; Jeffrey Craft; Rawan Al Lozi; Manushka Vaidya; Yifan Meng; Joseph O Deasy; Jeffrey D Bradley; Issam El Naqa
Journal:  Phys Med Biol       Date:  2011-02-18       Impact factor: 3.609

7.  Radiochemotherapy-induced changes of tumour vascularity and blood supply estimated by dynamic contrast-enhanced CT and fractal analysis in malignant head and neck tumours.

Authors:  A Abramyuk; V Hietschold; S Appold; R von Kummer; N Abolmaali
Journal:  Br J Radiol       Date:  2015-01       Impact factor: 3.039

Review 8.  Validation of functional imaging as a biomarker for radiation treatment response.

Authors:  C Jentsch; B Beuthien-Baumann; E G C Troost; G Shakirin
Journal:  Br J Radiol       Date:  2015-05-29       Impact factor: 3.039

9.  Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer.

Authors:  P Veit-Haibach; D De Ruysscher; W van Elmpt; M Das; Martin Hüllner; H Sharifi; K Zegers; B Reymen; P Lambin; J E Wildberger; E G C Troost
Journal:  Radiother Oncol       Date:  2013-09-14       Impact factor: 6.280

10.  Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer.

Authors:  Nadya Shusharina; Joseph Cho; Gregory C Sharp; Noah C Choi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.